Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ausems

Showing results (131-140 of 204) with videos related to

Pageof 21
Sort By:
Breast Cancer Research and Treatment|July 15, 2019
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriersBernadette A M Heemskerk-Gerritsen, Agnes Jager, Linetta B Koppert, et al.
Journal of Medical Genetics|September 22, 2022
Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial casesInge M M Lakeman, Mar D M Rodríguez-Girondo, Andrew Lee, et al.
Psycho-Oncology|March 9, 2011
Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromesC R M Lammens, E M A Bleiker, S Verhoef, et al.
Breast (Edinburgh, Scotland)|November 28, 2025
Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variantMaartje A C Schreurs, Muriel A Adank, Bernadette A M Heemskerk-Gerritsen, et al.
Journal of Assisted Reproduction and Genetics|August 24, 2017
BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGDI A P Derks-Smeets, T C van Tilborg, A van Montfoort, et al.
Journal of Medical Genetics|June 5, 2010
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypesMarielle W G Ruijs, Senno Verhoef, Matti A Rookus, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 5, 2009
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort StudyAntonis C Antoniou, Matti Rookus, Nadine Andrieu, et al.
BJU International|September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancerMichiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
Journal of the National Cancer Institute|March 20, 2015
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reductionB A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, et al.
Breast (Edinburgh, Scotland)|December 20, 2021
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort studyDelal Akdeniz, Mark van Barele, Bernadette A M Heemskerk-Gerritsen, et al.
Pageof 21

Showing results (131-140 of 204) with videos related to

Sort By:
Pageof 21
Breast Cancer Research and Treatment|July 15, 2019
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriersBernadette A M Heemskerk-Gerritsen, Agnes Jager, Linetta B Koppert, et al.
Journal of Medical Genetics|September 22, 2022
Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial casesInge M M Lakeman, Mar D M Rodríguez-Girondo, Andrew Lee, et al.
Psycho-Oncology|March 9, 2011
Distress in partners of individuals diagnosed with or at high risk of developing tumors due to rare hereditary cancer syndromesC R M Lammens, E M A Bleiker, S Verhoef, et al.
Breast (Edinburgh, Scotland)|November 28, 2025
Outcomes for ER-positive CHEK2 c.1100delC breast cancer patients compared with breast cancer patients without the variantMaartje A C Schreurs, Muriel A Adank, Bernadette A M Heemskerk-Gerritsen, et al.
Journal of Assisted Reproduction and Genetics|August 24, 2017
BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGDI A P Derks-Smeets, T C van Tilborg, A van Montfoort, et al.
Journal of Medical Genetics|June 5, 2010
TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypesMarielle W G Ruijs, Senno Verhoef, Matti A Rookus, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 5, 2009
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort StudyAntonis C Antoniou, Matti Rookus, Nadine Andrieu, et al.
BJU International|September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancerMichiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
Journal of the National Cancer Institute|March 20, 2015
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reductionB A M Heemskerk-Gerritsen, C Seynaeve, C J van Asperen, et al.
Breast (Edinburgh, Scotland)|December 20, 2021
Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort studyDelal Akdeniz, Mark van Barele, Bernadette A M Heemskerk-Gerritsen, et al.
Pageof 21